| Literature DB >> 27916558 |
Yunping Chen1, Lina Ba1, Wei Huang1, Yan Liu1, Hao Pan1, E Mingyao1, Pilong Shi1, Ye Wang1, Shuzhi Li1, Hanping Qi1, Hongli Sun1, Yonggang Cao2.
Abstract
Carvacrol (CAR) is a compound isolated from some essential oils, many studies have demonstrated its therapeutic potential on different diseases. This study aims to evaluate the protective effect of CAR against myocardial ischemia/reperfusion (I/R) injury in rats. Male adult rats underwent ligation of the left anterior descending coronary artery (LAD) in I/R models. Rats were treated with CAR after LAD. The levels of I/R- induced infarct size, cardiomyocyte apoptosis and cardiac functional impairment were examined. Levels of superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA) were detected by western blotting. Cardiomyocytes induced by hypoxic reperfusion (H/R) injury were tested by Hoechst 33258. Our results revealed that CAR administration significantly protected the heart function, attenuated myocardial infarct size, increased SOD and CAT levels, reduced MDA level and especially decreased cardiomyocytes apoptosis. Western blotting showed that CAR treatment up-regulated phosphorylated ERK (p-ERK), while producing no impact onp38 mitogen-activated protein kinase (p38MAPK) and c-Jun N-terminal kinase (JNK). The cardioprotection of CAR was reversed by the ERK inhibitor PD-98059, demonstrating the involvement of the MAPK/ERK pathway in the anti-apoptotic mechanisms of CAR. Besides, the results in vitro also showed the protective efficiency of CAR on cardiomyocytes H/R injury. Furthermore, pretreatment with CAR markedly increased the activation of Akt/eNOS pathway in cardiomyocytes subjected to H/R, and the protective effects of CAR were abolished in the presence of the Akt inhibitor LY294002. Therefore, the cardioprotective effects of CAR may be attributed to its antioxidant and antiapoptotic activities through activations of the MAPK/ERK and Akt/eNOS signaling pathways.Entities:
Keywords: Akt/eNOS; Carvacrol; Carvacrol (PubChem CID:10364); DAPI (PubChem CID:2954); Fluorescein dUTP (PubChem CID:86753173); MAPK/ERK; Myocardial ischemia/reperfusion injury; PD-98059 (PubChem CID:4713); Sodium pentobarbital (PubChem CID:23676152)
Mesh:
Substances:
Year: 2016 PMID: 27916558 DOI: 10.1016/j.ejphar.2016.11.053
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432